

Karel Pavelka

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6856925/karel-pavelka-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

187 papers	17,403 citations	47 h-index	131 g-index
236 ext. papers	21,696 ext. citations	4.4 avg, IF	6.8 L-index

#	Paper	IF	Citations
187	Delayed treatment with a tumor necrosis factor alpha blocker associated with worse outcomes in patients with spondyloarthritis: data from the Czech National Registry ATTRA.. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022 , 14, 1759720X221081649	3.8	
186	The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry.. <i>Rheumatology International</i> , 2022 , 42, 803	3.6	0
185	A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis. <i>Rheumatology and Therapy</i> , 2021 , 8, 1775-1787	4.4	0
184	S100A11 (calgizzarin) is released via NETosis in rheumatoid arthritis (RA) and stimulates IL-6 and TNF secretion by neutrophils. <i>Scientific Reports</i> , 2021 , 11, 6063	4.9	3
183	Sexual function in patients with idiopathic inflammatory myopathies: a cross-sectional study. <i>Rheumatology</i> , 2021 , 60, 5060-5072	3.9	0
182	The effect of a 24-week training focused on activities of daily living, muscle strengthening, and stability in idiopathic inflammatory myopathies: a monocentric controlled study with follow-up. <i>Arthritis Research and Therapy</i> , 2021 , 23, 173	5.7	2
181	Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin. <i>Biomedicines</i> , 2021 , 9,	4.8	1
180	Targeted and biological drugs in the treatment of inflammatory rheumatic diseases. <i>Vnitřní Lékarství</i> , 2021 , 67, 195-200	0.3	1
179	Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response. <i>Scientific Reports</i> , 2021 , 11, 11525	4.9	3
178	Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases. <i>Journal of Rheumatology</i> , 2021 , 48, 48-57	4.1	4
177	The dysregulation of monocyte subpopulations in individuals at risk of developing rheumatoid arthritis. <i>Rheumatology</i> , 2021 , 60, 1823-1831	3.9	1
176	The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. <i>Rheumatology</i> , 2021 , 60, 820-828	3.9	14
175	Knud Rasmussen Glacier Status Analysis Based on Historical Data and Moving Detection Using RPAS. <i>Applied Sciences (Switzerland)</i> , 2021 , 11, 754	2.6	0
174	Switching first-line targeted therapy after not reaching low disease activity within 6 months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry. <i>Arthritis Research and Therapy</i> , 2021 , 23, 11	5.7	4
173	Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study. <i>Scientific Reports</i> , 2021 , 11, 1	4.9	2785
172	Astronomical Investigation to Verify the Calendar Theory of the Nasca Lines. <i>Applied Sciences (Switzerland)</i> , 2021 , 11, 1637	2.6	
171	High miR-451 expression in peripheral blood mononuclear cells from subjects at risk of developing rheumatoid arthritis. <i>Scientific Reports</i> , 2021 , 11, 4719	4.9	1

170	Earthen Jewish Architecture of Southern Morocco: Documentation of Unfired Brick Synagogues and Mellahs in the Drâ-Tafilalet Region. <i>Applied Sciences (Switzerland)</i> , 2021 , 11, 1712	2.6	6
169	Clinical effectiveness and safety of intra-articular injection of HYALGO in the management of knee osteoarthritis symptoms: A multicenter prospective study. <i>Journal of Clinical Orthopaedics and Trauma</i> , 2021 , 19, 75-80	2.1	
168	Plasma heat shock protein 90 levels in patients with spondyloarthritis and their relation to structural changes: a cross-sectional study. <i>Biomarkers in Medicine</i> , 2021 , 15, 5-13	2.3	2
167	Prevalence and distribution of cartilage and bone damage at metacarpal head in healthy subjects. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 1394-1401	2.2	2
166	Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials. <i>Rheumatology International</i> , 2021 , 42, 205	3.6	
165	An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis. <i>Rheumatology</i> , 2020 , 59, 3858-3868	3.9	11
164	Impact of discordance between patient and evaluator global assessment on treatment outcomes in 14'868 patients with spondyloarthritis. <i>Rheumatology</i> , 2020 , 59, 2455-2461	3.9	4
163	Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study. <i>ACR Open Rheumatology</i> , 2020 , 2, 119-127	3.5	11
162	S100A4 is elevated in axial spondyloarthritis: a potential link to disease severity. <i>BMC Rheumatology</i> , 2020 , 4, 13	2.9	0
161	Upadacitinib placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients. <i>Drugs in Context</i> , 2020 , 9,	5.2	1
160	Chemokine and Cytokine Profiles in Patients with Hand Osteoarthritis. <i>Biomolecules</i> , 2020 , 11,	5.9	2
159	Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA. <i>Rheumatology</i> , 2020 , 59, 1640-1650	3.9	6
158	Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 183-192	5.4	3
157	Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities. <i>RMD Open</i> , 2020 , 6,	5.9	5
156	Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. <i>RMD Open</i> , 2020 , 6,	5.9	10
155	STRUCTURE FROM MOTION PROCESSING OF ANALOGUE IMAGES CAPTURED BY ROLLEI METRIC CAMERA, DIGITIZED WITH VARIOUS SCANNING RESOLUTION. <i>Acta Polytechnica</i> , 2020 , 60, 288-302	1	2
154	Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 17-24	5.3	10
153	Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1536-1544	2.4	23

152	Prevalence and distribution of cartilage damage at the metacarpal head level in rheumatoid arthritis and osteoarthritis: an ultrasound study. <i>Rheumatology</i> , 2019 , 58, 1206-1213	3.9	10
151	Pro-inflammatory S100A11 is elevated in inflammatory myopathies and reflects disease activity and extramuscular manifestations in myositis. <i>Cytokine</i> , 2019 , 116, 13-20	4	11
150	Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution. <i>Rheumatology</i> , 2019 , 58, 2221-2229	3.9	6
149	Examples of different techniques for glaciers motion monitoring using InSAR and RPAS. <i>European Journal of Remote Sensing</i> , 2019 , 52, 219-232	2.9	4
148	Serum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study. <i>Rheumatology International</i> , 2019 , 39, 1037-1043	3.6	4
147	Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice. <i>Clinical Rheumatology</i> , 2019 , 38, 2411-2421	3.9	4
146	The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients. <i>Arthritis Research and Therapy</i> , 2019 , 21, 77	5.7	33
145	Study of Erbil Al-Qala citadel time changes by comparison of historical and contemporary image data. <i>European Journal of Remote Sensing</i> , 2019 , 52, 202-208	2.9	4
144	An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019 , 21, 84	5.7	21
143	Cross-sectional study of patients with axial spondyloarthritis fulfilling imaging arm of ASAS classification criteria: baseline clinical characteristics and subset differences in a single-centre cohort. <i>BMJ Open</i> , 2019 , 9, e024713	3	7
142	Metabolites of type I, II, III, and IV collagen may serve as markers of disease activity in axial spondyloarthritis. <i>Scientific Reports</i> , 2019 , 9, 11218	4.9	7
141	FRI0378 DOES DRUG EFFECTIVENESS OF 2ND AND 3RD TNF INHIBITORS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS DEPEND ON THE REASON FROM WITHDRAWAL FROM THE PREVIOUS TREATMENT? â€”RESULTS FROM THE EUROSPA RESEARCH COLLABORATION 2019 ,		2
140	Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?. <i>RMD Open</i> , 2019 , 5, e000994	5.9	14
139	Treat-to-target strategy for knee osteoarthritis. International technical expert panel consensus and good clinical practice statements. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2019 , 11, 1759720X19893800	3.8	18
138	RPAS for documentation of Nazca aqueducts. <i>European Journal of Remote Sensing</i> , 2019 , 52, 174-181	2.9	6
137	Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study. <i>Rheumatology International</i> , 2019 , 39, 469-478	3.6	15
136	Changes of patient-reported outcomes and protein fingerprint biomarkers after exercise therapy for axial spondyloarthritis. <i>Clinical Rheumatology</i> , 2019 , 38, 173-179	3.9	6
135	Real world use of secukinumab for treatment of axial spondyloarthritis and psoriatic arthritis: nationwide results from the ATTRA registry. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37, 342-343	2.2	7

134	S100A11 (calgizzarin) is released by circulating mononuclear cells and its elevated plasma levels distinguish systemic lupus erythematosus patients from healthy individuals. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37, 338-339	2.2	1
133	Metabolites of C-reactive protein and vimentin are associated with disease activity of axial spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37, 358-366	2.2	6
132	Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein. <i>Clinical Rheumatology</i> , 2018 , 37, 2055-2062	3.9	12
131	Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial. <i>Clinical Rheumatology</i> , 2018 , 37, 1417-1420	3.9	1
130	Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1276-1282	2.4	44
129	Using of both hyperspectral aerial sensing and RPAS multispectral sensing for potential archaeological sites detection 2018 ,		1
128	Biomarkers of hand osteoarthritis. <i>Rheumatology International</i> , 2018 , 38, 725-735	3.6	11
127	Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis. <i>Patient</i> , 2018 , 11, 329-340	3.7	5
126	AUTOMATIC CLASSIFICATION OF POINT CLOUDS FOR HIGHWAY DOCUMENTATION. <i>Acta Polytechnica</i> , 2018 , 58, 165	1	12
125	High Resolution Drone Surveying of the Pista Geoglyph in Palpa, Peru. <i>Geosciences (Switzerland)</i> , 2018 , 8, 479	2.7	7
124	Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries. <i>RMD Open</i> , 2018 , 4, e000809	5.9	13
123	Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent. <i>BioDrugs</i> , 2018 , 32, 397-404	7.9	59
122	Lower serum clusterin levels in patients with erosive hand osteoarthritis are associated with more pain. <i>BMC Musculoskeletal Disorders</i> , 2018 , 19, 264	2.8	12
121	Enthesal involvement in patients with systemic lupus erythematosus: an ultrasound study. <i>Rheumatology</i> , 2018 , 57, 1822-1829	3.9	14
120	Mapping the relationship between clinical and quality-of-life outcomes in patients with ankylosing spondylitis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017 , 17, 203-211	2.2	8
119	Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration. <i>Journal of Rheumatology</i> , 2017 , 44, 162-169	4.1	13
118	Use of Intraarticular Hyaluronic Acid in the Management of Knee Osteoarthritis in Clinical Practice. <i>Arthritis Care and Research</i> , 2017 , 69, 1287-1296	4.7	65
117	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 960-974	7.4	1649

116	UAV remote sensing capability for precision agriculture, forestry and small natural reservation monitoring 2017 ,		3
115	Calgizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017 , 19, 79	5.7	24
114	Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1679-1687	2.4	99
113	Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access. <i>Rheumatology International</i> , 2017 , 37, 1469-1479	3.6	12
112	Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONDroitin versus CElecoxib versus Placebo Trial (CONCEPT). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1537-1543	2.4	54
111	GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 869-877	2.4	79
110	Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA)". <i>Clinical Rheumatology</i> , 2017 , 36, 773-779	3.9	26
109	Association between circulating miRNAs and spinal involvement in patients with axial spondyloarthritis. <i>PLoS ONE</i> , 2017 , 12, e0185323	3.7	25
108	A 12-week randomized, double-blind, placebo-controlled multicenter study of choline-stabilized orthosilicic acid in patients with symptomatic knee osteoarthritis. <i>BMC Musculoskeletal Disorders</i> , 2017 , 18, 2	2.8	8
107	Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. <i>Arthritis Research and Therapy</i> , 2017 , 19, 285	5.7	109
106	Functional non-synonymous variants of ABCG2 and gout risk. <i>Rheumatology</i> , 2017 , 56, 1982-1992	3.9	44
105	Treatment of atlanto-axial subluxation secondary to rheumatoid arthritis by short segment stabilization with polyaxial screws. <i>Acta Neurochirurgica</i> , 2017 , 159, 1791-1801	3	3
104	The relationship between synovitis quantified by an ultrasound 7-joint inflammation score and physical disability in rheumatoid arthritis - a cohort study. <i>Arthritis Research and Therapy</i> , 2017 , 19, 5	5.7	8
103	Interleukin-20 is triggered by TLR ligands and associates with disease activity in patients with rheumatoid arthritis. <i>Cytokine</i> , 2017 , 97, 187-192	4	10
102	The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. <i>PLoS ONE</i> , 2017 , 12, e0175207	3.7	63
101	Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study. <i>PLoS ONE</i> , 2017 , 12, e0183420	3.7	19
100	Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis. <i>Rheumatology</i> , 2016 , 55, 230-6	3.9	16
99	Novel dysfunctional variant in ABCG2 as a cause of severe tophaceous gout: biochemical, molecular genetics and functional analysis. <i>Rheumatology</i> , 2016 , 55, 191-4	3.9	19

98	A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 96-102	2.4	47
97	MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 170-7	2.4	36
96	Serum and bone pentosidine in patients with low impact hip fractures and in patients with advanced osteoarthritis. <i>BMC Musculoskeletal Disorders</i> , 2016 , 17, 308	2.8	15
95	Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. <i>Arthritis Research and Therapy</i> , 2016 , 18, 50	5.7	27
94	MicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016 , 18, 124	5.7	35
93	Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. <i>Drugs and Aging</i> , 2016 , 33, 75-85	4.7	68
92	An update on biomarkers in axial spondyloarthritis. <i>Autoimmunity Reviews</i> , 2016 , 15, 501-9	13.6	49
91	Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission. <i>PLoS ONE</i> , 2016 , 11, e0165498	3.7	8
90	Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1336-42	2.4	47
89	Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2016 , 18, 275	5.7	32
88	Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study. <i>RMD Open</i> , 2016 , 2, e000228	5.9	10
87	Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab. <i>Rheumatology</i> , 2016 , 55, 1466-76	3.9	16
86	Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice. <i>Clinical Rheumatology</i> , 2015 , 34, 563-71	3.9	30
85	Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease. <i>Rheumatology</i> , 2015 , 54, 2273-82	3.9	14
84	High levels of metastasis-inducing S100A4 protein and treatment outcome in early rheumatoid arthritis: data from the PERAC cohort. <i>Biomarkers</i> , 2015 , 20, 47-51	2.6	9
83	A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate. <i>Journal of Rheumatology</i> , 2015 , 42, 912-9	4.1	49
82	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 963-9	2.4	27
81	Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. <i>BMC Musculoskeletal Disorders</i> , 2015 , 16, 176	2.8	34

80	Hyperuricemia and gout due to deficiency of hypoxanthine-guanine phosphoribosyltransferase in female carriers: New insight to differential diagnosis. <i>Clinica Chimica Acta</i> , 2015 , 440, 214-7	6.2	10
79	Progranulin Is Associated with Disease Activity in Patients with Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2015 , 2015, 740357	4.3	23
78	Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015 , 17, 252	5.7	42
77	Pro-inflammatory effects of interleukin-35 in rheumatoid arthritis. <i>Cytokine</i> , 2015 , 73, 36-43	4	39
76	Interleukin 35 Synovial Fluid Levels Are Associated with Disease Activity of Rheumatoid Arthritis. <i>PLoS ONE</i> , 2015 , 10, e0132674	3.7	24
75	Elevated serum prolactin levels as a marker of inflammatory arthritis in psoriasis vulgaris. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2015 , 159, 562-8	1.7	4
74	Creating of DSM Based on RPAS Measurement and Accuracy Testing. <i>Lecture Notes in Geoinformation and Cartography</i> , 2015 , 173-188	0.3	1
73	Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. <i>BMC Musculoskeletal Disorders</i> , 2014 , 15, 14	2.8	41
72	The metastasis-associated protein S100A4 promotes the inflammatory response of mononuclear cells via the TLR4 signalling pathway in rheumatoid arthritis. <i>Rheumatology</i> , 2014 , 53, 1520-6	3.9	45
71	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 492-509	2.4	1487
70	The association between lean mass and bone mineral content in the high disease activity group of adult patients with juvenile idiopathic arthritis. <i>BMC Musculoskeletal Disorders</i> , 2014 , 15, 51	2.8	9
69	Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. <i>Lancet, The</i> , 2014 , 383, 321-32	4.0	196
68	Decreased circulating visfatin is associated with improved disease activity in early rheumatoid arthritis: data from the PERAC cohort. <i>PLoS ONE</i> , 2014 , 9, e103495	3.7	17
67	Complex analysis of urate transporters SLC2A9, SLC22A12 and functional characterization of non-synonymous allelic variants of GLUT9 in the Czech population: no evidence of effect on hyperuricemia and gout. <i>PLoS ONE</i> , 2014 , 9, e107902	3.7	29
66	Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis. <i>Arthritis Research and Therapy</i> , 2014 , 16, 460	5.7	8
65	Etanercept in moderate rheumatoid arthritis: PRESERVE study results from central/eastern Europe, Latin America and Asia. <i>International Journal of Clinical Rheumatology</i> , 2014 , 9, 415-430	1.5	2
64	Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1898-904	2.4	140
63	Physiological effects of oral glucosamine on joint health: current status and consensus on future research priorities. <i>BMC Research Notes</i> , 2013 , 6, 115	2.3	19

62	Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes. <i>Calcified Tissue International</i> , 2013 , 92, 354-61	3.9	57
61	Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. <i>Lancet, The</i> , 2013 , 381, 918-29	4.0	266
60	Bone status in adults with early-onset juvenile idiopathic arthritis following 1-year anti-TNF β therapy and discontinuation of glucocorticoids. <i>Rheumatology International</i> , 2013 , 33, 2001-7	3.6	9
59	Changes in structure and symptoms in knee osteoarthritis and prediction of future knee replacement over 8 years. <i>Calcified Tissue International</i> , 2013 , 93, 502-7	3.9	14
58	The level of fatty acid-binding protein 4, a novel adipokine, is increased in rheumatoid arthritis and correlates with serum cholesterol levels. <i>Cytokine</i> , 2013 , 64, 441-7	4	13
57	Leflunomide in psoriatic arthritis: results from a large European prospective observational study. <i>Arthritis Care and Research</i> , 2013 , 65, 464-70	4.7	52
56	EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1125-35	2.4	753
55	Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. <i>Lancet, The</i> , 2013 , 381, 1541-50	4.0	460
54	Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study. <i>Clinical Rheumatology</i> , 2013 , 32, 1275-81	3.9	15
53	Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry. <i>Clinical Rheumatology</i> , 2013 , 32, 1451-8	3.9	13
52	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 482-92	2.4	87
51	Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1621-7	2.4	81
50	A7.3 Association of Circulating miR-223 and miR-16 with Disease Activity in Patients with Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A48.3-A49	2.4	
49	No effect of physiotherapy on the serum levels of adipocytokines in patients with ankylosing spondylitis. <i>Clinical Rheumatology</i> , 2012 , 31, 67-71	3.9	15
48	Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs. <i>Rheumatology</i> , 2012 , 51 Suppl 5, v12-21	3.9	14
47	Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement. <i>Journal of Rheumatology</i> , 2012 , 39, 836-40	4.1	20
46	Biologic registries in rheumatology: lessons learned and expectations for the future. <i>Autoimmunity Reviews</i> , 2012 , 12, 329-36	13.6	18
45	Hip fracture incidence from 1981 to 2009 in the Czech Republic as a basis of the country-specific FRAX model. <i>Calcified Tissue International</i> , 2012 , 90, 365-72	3.9	18

44	Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 374-7	2.4	52
43	Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. <i>Journal of Bone and Joint Surgery - Series A</i> , 2012 , 94, 2113-9	5.6	79
42	Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1950-4	2.4	73
41	Pentosidine, an advanced glycation end-product, may reflect clinical and morphological features of hand osteoarthritis. <i>Open Rheumatology Journal</i> , 2012 , 6, 64-9	0.2	5
40	Efficacy of different doses of rituximab for the treatment of RA: data From the CERERRA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, A13.2-A14	2.4	
39	Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2011 , 13, R122	5.7	52
38	The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy. <i>Cytokine</i> , 2011 , 55, 116-21	4	24
37	Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1895-904	2.4	274
36	Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1575-80	2.4	157
35	Adipokine profile is modulated in subcutaneous adipose tissue by TNF inhibitors in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 2054-6	2.4	8
34	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 909-20	2.4	308
33	Modulation of subcutaneous adipose tissue adipokines by TNF-blockade therapy in patients with inflammatory arthritides. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, A85-A85	2.4	
32	Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1999-2002	2.4	59
31	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 964-75	2.4	1210
30	Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1410-1	2.4	78
29	Efficacy and safety of piascladine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. <i>Clinical Rheumatology</i> , 2010 , 29, 659-70	3.9	51
28	Metastasis-inducing S100A4 protein is associated with the disease activity of rheumatoid arthritis. <i>Rheumatology</i> , 2009 , 48, 1590-4	3.9	32
27	Prospective new biological therapies for rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2009 , 9, 102-7	13.6	107

26	Self-reported compliance with osteoporosis medication-qualitative aspects and correlates. <i>Maturitas</i> , 2008 , 60, 223-9	5	12
25	Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. <i>Arthritis and Rheumatism</i> , 2008 , 58, 3319-29		458
24	Up-regulation of metastasis-promoting S100A4 (Mts-1) in rheumatoid arthritis: putative involvement in the pathogenesis of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007 , 56, 779-89		74
23	The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled study with primary end points at two months after the end of a three-month treatment period. <i>Arthritis and Rheumatism</i> , 2007 , 56, 4055-64		52
22	Knowledge of osteoporosis correlated with hormone therapy use and health status. <i>Maturitas</i> , 2007 , 56, 21-9	5	12
21	Some principles of the development of a clinical database/national register of selected inflammatory rheumatic diseases in the Czech Republic. <i>International Journal of Medical Informatics</i> , 2006 , 75, 216-23	5.3	7
20	S100A4 (Mts1): is there any relation to the pathogenesis of rheumatoid arthritis?. <i>Autoimmunity Reviews</i> , 2006 , 5, 129-31	13.6	24
19	The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. <i>Arthritis and Rheumatism</i> , 2006 , 54, 26-37		1385
18	Clinical significance of the long-term symptom-modifying effects of glucosamine sulfate: comment on the article by Brandt and Mazzuca. <i>Arthritis and Rheumatism</i> , 2006 , 54, 2339-41; author reply 2341-3		4
17	Adalimumab in the treatment of rheumatoid arthritis. <i>Aging Health</i> , 2006 , 2, 533-545		5
16	COL6A1, the candidate gene for ossification of the posterior longitudinal ligament, is associated with diffuse idiopathic skeletal hyperostosis in Japanese. <i>Spine</i> , 2005 , 30, 2321-4	3.3	75
15	Transdermal fentanyl for the treatment of pain caused by osteoarthritis of the knee or hip: an open, multicentre study. <i>BMC Musculoskeletal Disorders</i> , 2005 , 6, 31	2.8	16
14	Benefits of transdermal fentanyl in patients with rheumatoid arthritis or with osteoarthritis of the knee or hip: an open-label study to assess pain control. <i>Current Medical Research and Opinion</i> , 2004 , 20, 1967-77	2.5	18
13	Natural selection and population history in the human angiotensinogen gene (AGT): 736 complete AGT sequences in chromosomes from around the world. <i>American Journal of Human Genetics</i> , 2004 , 74, 898-916	11	107
12	Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. <i>Lancet, The</i> , 2004 , 363, 675-81	40	1454
11	Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. <i>Menopause</i> , 2004 , 11, 138-43	2.5	92
10	Symptomatic treatment of osteoarthritis: paracetamol or NSAIDs?. <i>International Journal of Clinical Practice</i> , 2004 , 58, 5-12	2.9	12
9	Monoclonal antibodies to human cartilage oligomeric matrix protein: epitope mapping and characterization of sandwich ELISA. <i>Clinica Chimica Acta</i> , 2003 , 328, 59-69	6.2	34

8	Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. <i>Archives of Internal Medicine</i> , 2002 , 162, 2113-23		476
7	Oral therapy with proteolytic enzymes decreases excessive TGF-beta levels in human blood. <i>Cancer Chemotherapy and Pharmacology</i> , 2001 , 47 Suppl, S10-5	3.5	44
6	Comparaison des signes cliniques, radiographiques, biologiques et scintigraphiques dans l'arthrose fœsive et non fœsive de la main. Rŕsultats aprŕ deux ans de suivi. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2000 , 67, 127-133	0.1	
5	Osteonecrosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2000 , 14, 399-414	5.3	18
4	Predictive map of Ixodes ricinus high-incidence habitats and a tick-borne encephalitis risk assessment using satellite data. <i>Experimental and Applied Acarology</i> , 1998 , 22, 417-33	2.1	60
3	Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. <i>Clinical Drug Investigation</i> , 1998 , 16, 421-9	3.2	23
2	Characterization of monoclonal antibodies recognizing different fragments of cartilage oligomeric matrix protein in human body fluids. <i>Archives of Biochemistry and Biophysics</i> , 1997 , 341, 8-16	4.1	43
1	Glycosaminoglycan polysulfuric acid (GAGPS) in osteoarthritis of the knee. <i>Osteoarthritis and Cartilage</i> , 1995 , 3, 15-23	6.2	19